Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 28, 2026

Oct 28, 2026

•

3 min read

Biotech & Pharma Updates | October 28, 2026

🧬 Eli Lilly's (retatrutide) beats Novo's Ozempic in Ph3 trial for type 2 diabetes on blood sugar and weight loss, Biogen posts third consecutive quarter of revenue growth, reaching $2.8B with Apellis integration boost, Ferring Pharmaceuticals to acquire Gameto for up to $1.4B, adding next-gen IVF technology Fertilo

Christian Cuchapin, +1

Biotech & Pharma Updates | October 27, 2026

Oct 27, 2026

•

3 min read

Biotech & Pharma Updates | October 27, 2026

🧬 GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) nearly quadruples progression-free survival in Ph3 B7-H3-targeted osteosarcoma trial, Anthropic files IPO, revealing drug R&D ambitions including molecular biology lab and pharma partnerships, FDA approves Pfizer's Talzenna (talazoparib)-Xtandi (enzalutamide) combo for HRR-mutated metastatic hormone-sensitive prostate cancer based on Ph3 data

Christian Cuchapin, +1

Biotech & Pharma Updates | October 26, 2026

Oct 26, 2026

•

4 min read

Biotech & Pharma Updates | October 26, 2026

🧬 Akeso, Summit Therapeutics' (ivonescimab) beats AstraZeneca's Imfinzi in Ph3 biliary tract cancer trial with 25% lower death risk, Pathos AI raises $237M Series E, led by Bristol Myers Squibb, scaling AI-driven drug development platform, Johnson & Johnson's JNJ-6143 (JNJ-6143) shows 75% overall response rate in Ph1 metastatic castration-resistant prostate cancer trial

Christian Cuchapin, +1

Biotech & Pharma Updates | October 23, 2026

Oct 23, 2026

•

3 min read

Biotech & Pharma Updates | October 23, 2026

🧬 Gilead Sciences acquires PepStar Therapeutics' IL-23R inhibitor program for $1.3B upfront, Alnylam plans pivotal trial for brezosiran (ALN-HTT02) targeting huntingtin protein in Huntington's disease after Ph1b success, FDA lifts clinical hold on Aardvark Therapeutics' ARD-101 after new cardiac safety data clears concerns

Christian Cuchapin, +1

Biotech & Pharma Updates | October 22, 2026

Oct 22, 2026

•

3 min read

Biotech & Pharma Updates | October 22, 2026

🧬 Roche's Vabysmo hits $1.38B quarterly sales, meets analyst expectations after prolonged growth slowdown, AstraZeneca's Ultomiris (ravulizumab) wins FDA accelerated approval for immunoglobulin A nephropathy, its fifth indication, FDA accepts Biohaven's Vyglxia (troriluzole) resubmission for spinocerebellar ataxia with advisory committee meeting planned

Christian Cuchapin, +1

Biotech & Pharma Updates | October 21, 2026

Oct 21, 2026

•

3 min read

Biotech & Pharma Updates | October 21, 2026

🧬 GSK, Ionis Pharmaceuticals win FDA approval for Hibsago (bepirovirsen) targeting hepatitis B virus in chronic hepatitis B infection following Ph3 success, Priovant Therapeutics seeks label expansion for Lisraya (brepocitinib) after Ph3 success in non-infectious uveitis, OpenAI acquires Orchestra Bio, combining AI platforms to accelerate drug development workflows

Christian Cuchapin, +1

Biotech & Pharma Updates | October 20, 2026

Oct 20, 2026

•

3 min read

Biotech & Pharma Updates | October 20, 2026

🧬 GSK's Jemperli (dostarlimab) receives FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer based on Ph2 data, Eli Lilly, METiS TechBio partner on AI-driven LNP drug delivery platform, up to $1.1B milestones, Gilead Sciences' (emvistegrast) meets Ph2 primary endpoint in moderately to severely active ulcerative colitis, Ph3 planned

Christian Cuchapin, +1

Biotech & Pharma Updates | October 19, 2026

Oct 19, 2026

•

3 min read

Biotech & Pharma Updates | October 19, 2026

🧬 Merck KGaA acquires Silence Therapeutics for $1.3B, gaining promising siRNA blood cancer drug divesiran, Disc Medicine's (bitopertin) Ph3 trial meets all endpoints for erythropoietic protoporphyria, paving way for FDA resubmission, Sanofi breaks ground on new Frankfurt insulin manufacturing facility, targeting full production by 2032

Christian Cuchapin, +1

The Diseases We Couldn't Afford to Study Until Now

Oct 17, 2026

•

4 min read

The Diseases We Couldn't Afford to Study Until Now

Deciding which diseases are worth studying has never been a purely scientific question. It has always come down to how much evidence one person can hold in their head. AI is changing that.

Anis Fahandej-Sadi

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 28, 2026

Biotech & Pharma Updates | October 27, 2026

Biotech & Pharma Updates | October 26, 2026

Biotech & Pharma Updates | October 23, 2026

Biotech & Pharma Updates | October 22, 2026

Biotech & Pharma Updates | October 21, 2026

Biotech & Pharma Updates | October 20, 2026

Biotech & Pharma Updates | October 19, 2026

The Diseases We Couldn't Afford to Study Until Now

TLDR Biotech

FAQ

Media Partners